<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23725050</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Immunologic hypo- or non-responder in natural dengue virus infection.</ArticleTitle><Pagination><StartPage>34</StartPage><MedlinePgn>34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1423-0127-20-34</ELocationID><Abstract><AbstractText>Serologically defined primary dengue virus infection and/or subsequent homologous serotype infection is known to be associated with less severe disease as compared with secondary subsequent heterologous serotype infection. In geographical locales of high dengue endemicity, almost all individuals in the population are infected at some point in time and should therefore are at high risk of secondary infection. Interestingly, dengue viremia in healthy blood donors whose sera apparently lack detectable levels of specific antibody to dengue viral antigens has been reported. The incidence rate of potential immunologic hypo- or non-responders following natural primary dengue virus infection in dengue endemic regions, who do become immune responders only after repeated exposure, has not been described. These are the patients who may be diagnosed as primary infection in the subsequent infection, but actually are secondary infection. This concept has important implications with regards to the hypothesis of immunological enhancement of dengue pathogenesis, which has largely been advanced based on empirical observations and/or from in vitro experimental assays. The fact that dengue na&#xef;ve travelers can suffer from severe dengue upon primary exposure while visiting dengue endemic countries underscores one of the major problems in explaining the role of immune enhancement in the pathogenesis of severe dengue virus infection. This evidence suggests that the mechanism(s) leading to severe dengue may not be associated with pre-existing enhancing antibody. Consequently, we propose a new paradigm for dengue virus infection classification. These include a) patients with na&#xef;ve primary infection, b) those that are serologically defined primary in dengue endemic zones and c) those who are serologically defined secondary dengue virus infection. We submit that clarity with regards to such definitions may help facilitate the delineation of the potential mechanisms of severe dengue virus infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perng</LastName><ForeName>Guey Chuen</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Medical College, National Cheng Kung University, Tainan, 70101, Taiwan. gperng@mail.ncku.edu.tw</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chokephaibulkit</LastName><ForeName>Kulkanya</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23725050</ArticleId><ArticleId IdType="pmc">PMC3680176</ArticleId><ArticleId IdType="doi">10.1186/1423-0127-20-34</ArticleId><ArticleId IdType="pii">1423-0127-20-34</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med. 1970;42(5):311&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2591704</ArticleId><ArticleId IdType="pubmed">5419206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol. 1984;120(5):653&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao DY, Lin TH, Hwang KP, Huang JH, Liu CC, King CC. 1998 dengue hemorrhagic fever epidemic in Taiwan. Emerg Infect Dis. 2004;10(3):552&#x2013;554. doi: 10.3201/eid1003.020518.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1003.020518</ArticleId><ArticleId IdType="pmc">PMC3322789</ArticleId><ArticleId IdType="pubmed">15116715</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer E, Schwartz E. A travel medicine view of dengue and dengue hemorrhagic fever. Travel Med Infect Dis. 2009;7(5):278&#x2013;283. doi: 10.1016/j.tmaid.2009.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2009.05.002</ArticleId><ArticleId IdType="pubmed">19747662</ArticleId></ArticleIdList></Reference><Reference><Citation>Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009;6(10):e1000171. doi: 10.1371/journal.pmed.1000171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000171</ArticleId><ArticleId IdType="pmc">PMC2762316</ArticleId><ArticleId IdType="pubmed">19859541</ArticleId></ArticleIdList></Reference><Reference><Citation>Thai KT, Binh TQ, Giao PT, Phuong HL, le Hung Q, Van Nam N, Nga TT, Groen J, Nagelkerke N, de Vries PJ. Seroprevalence of dengue antibodies, annual incidence and risk factors among children in southern Vietnam. Trop Med Int Health. 2005;10(4):379&#x2013;386. doi: 10.1111/j.1365-3156.2005.01388.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3156.2005.01388.x</ArticleId><ArticleId IdType="pubmed">15807802</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI, Mercado JC, Cuadra R, Rocha J, Perez MA, Silva S, Rocha C, Harris E. Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg. 2006;74(3):449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525106</ArticleId></ArticleIdList></Reference><Reference><Citation>Stramer SL, Linnen JM, Carrick JM, Foster GA, Krysztof DE, Zou S, Dodd RY, Tirado-Marrero LM, Hunsperger E, Santiago GA, Munoz-Jordan JL, Tomashek KM. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion. 2012;52(8):1657&#x2013;1666. doi: 10.1111/j.1537-2995.2012.03566.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2012.03566.x</ArticleId><ArticleId IdType="pubmed">22339201</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen LR, Tomashek KM, Biggerstaff BJ. Estimated prevalence of dengue viremia in Puerto Rican blood donations, 1995 through 2010. Transfusion. 2012;52(8):1647&#x2013;1651. doi: 10.1111/j.1537-2995.2011.03529.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2011.03529.x</ArticleId><ArticleId IdType="pubmed">22304614</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince HE, Yeh C, Lape-Nixon M. Utility of IgM/IgG ratio and IgG avidity for distinguishing primary and secondary dengue virus infections using sera collected more than 30 days after disease onset. Clin Vaccine Immunol. 2011;18(11):1951&#x2013;1956. doi: 10.1128/CVI.05278-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05278-11</ArticleId><ArticleId IdType="pmc">PMC3209020</ArticleId><ArticleId IdType="pubmed">21880858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Chen LH, Massad E, Wilson ME. Threat of dengue to blood safety in dengue-endemic countries. Emerg Infect Dis. 2009;15(1):8&#x2013;11. doi: 10.3201/eid1501.071097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1501.071097</ArticleId><ArticleId IdType="pmc">PMC2660677</ArticleId><ArticleId IdType="pubmed">19116042</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo D, Ng LC, Lam S. Is dengue a threat to the blood supply? Transfus Med. 2009;19(2):66&#x2013;77. doi: 10.1111/j.1365-3148.2009.00916.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3148.2009.00916.x</ArticleId><ArticleId IdType="pmc">PMC2713854</ArticleId><ArticleId IdType="pubmed">19392949</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias LL, Amarilla AA, Poloni TR, Covas DT, Aquino VH, Figueiredo LT. Detection of dengue virus in sera of Brazilian blood donors. Transfusion. 2012;52(8):1667&#x2013;1671. doi: 10.1111/j.1537-2995.2012.03729.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2012.03729.x</ArticleId><ArticleId IdType="pubmed">22670858</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott H. A History of Tropical Medicine. Baltimer: The Williams &amp; Wilkins Company; 1939.</Citation></Reference><Reference><Citation>Chastel C. Eventual role of asymptomatic cases of dengue for the introduction and spread of dengue viruses in non-endemic regions. Front Physiol. 2012;3:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315825</ArticleId><ArticleId IdType="pubmed">22479252</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A, Zarei S, Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine. 2008;26(2):269&#x2013;276. doi: 10.1016/j.vaccine.2007.10.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.10.044</ArticleId><ArticleId IdType="pubmed">18037544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 1989;87(3A):36S&#x2013;40S.</Citation><ArticleIdList><ArticleId IdType="pubmed">2528297</ArticleId></ArticleIdList></Reference><Reference><Citation>Poordad F, Khungar V. Emerging therapeutic options in hepatitis C virus infection. Am J Manag Care. 2011;17(Suppl 4):S123&#x2013;S130.</Citation><ArticleIdList><ArticleId IdType="pubmed">21767068</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 1996;14(4):337&#x2013;343. doi: 10.1016/0264-410X(95)00168-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(95)00168-Z</ArticleId><ArticleId IdType="pubmed">8744562</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma'roef C, Erlin, Sutaryo, Porter KR, Halstead SB. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996. Am J Trop Med Hyg. 1999;61(3):412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">10497982</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Foo W, Earnest A, Sremulanathan S, Paton NI. Seroepidemiology of dengue in the adult population of Singapore. Trop Med Int Health. 2004;9(2):305&#x2013;308. doi: 10.1046/j.1365-3156.2003.01177.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-3156.2003.01177.x</ArticleId><ArticleId IdType="pubmed">15040570</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira MG, Costa MC, Barreto ML, Barreto FR. [Epidemiology of dengue in Salvador-Bahia, 1995-1999] Rev Soc Bras Med Trop. 2001;34(3):269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">11460213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashiro T, Disla M, Petit A, Taveras D, Castro-Bello M, Lora-Orste M, Vardez S, Cesin AJ, Garcia B, Nishizono A. Seroprevalence of IgG specific for dengue virus among adults and children in Santo Domingo, Dominican Republic. Am J Trop Med Hyg. 2004;71(2):138&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">15306701</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturrino-Monge R, Avila-Aguero ML, Avila-Aguero CR, Moya-Moya T, Canas-Coto A, Camacho-Badilla K, Zambrano-Mora B. Seroprevalence of dengue virus antibodies in asymptomatic Costa Rican children, 2002-2003: a pilot study. Rev Panam Salud Publica. 2006;20(1):39&#x2013;43. doi: 10.1590/S1020-49892006000700005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1020-49892006000700005</ArticleId><ArticleId IdType="pubmed">17018223</ArticleId></ArticleIdList></Reference><Reference><Citation>Comach G, Blair PJ, Sierra G, Guzman D, Soler M, de Quintana MC, Bracho-Labadie M, Camacho D, Russell KL, Olson JG, Kochel TJ. Dengue virus infections in a cohort of schoolchildren from Maracay, Venezuela: a 2-year prospective study. Vector Borne Zoonotic Dis. 2009;9(1):87&#x2013;92. doi: 10.1089/vbz.2007.0213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vbz.2007.0213</ArticleId><ArticleId IdType="pubmed">18788903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed H, Tomashek KM, Stramer SL, Hunsperger E. Prevalence of anti-dengue immunoglobulin G antibodies among American Red Cross blood donors in Puerto Rico, 2006. Transfusion. 2012;52(8):1652&#x2013;1656. doi: 10.1111/j.1537-2995.2011.03492.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2011.03492.x</ArticleId><ArticleId IdType="pubmed">22224623</ArticleId></ArticleIdList></Reference><Reference><Citation>Siler JF, Hall MW, Hitchins AP. Dengue: Its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity and prevention. Philippine J Sci. 1926;29:1&#x2013;340.</Citation></Reference><Reference><Citation>Simmons JS, St. John JH, Reynolds FHK. Experimental studies of dengue. Philippine J Sci. 1931;44:1&#x2013;251.</Citation></Reference><Reference><Citation>Rice L. Dengue Fever: A clinical report of the Galveston epidemic of 1922. Am J Trop Med Hyg. 1923;III(2):73&#x2013;90.</Citation></Reference><Reference><Citation>Lane FF. A clinical study of 100 cases of dengue at At. Thomas. US Naval Med Bull. 1918;1(12):615&#x2013;623.</Citation></Reference><Reference><Citation>Sharp WB. Immunity in dengue fever. Am J Trop Med Hyg. 1934;15(3):247&#x2013;264.</Citation></Reference><Reference><Citation>Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI. Cost-effectiveness of a pediatric dengue vaccine. Vaccine. 2004;22(9&#x2013;10):1275&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003657</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP Jr, Statler JD, Innis BL. Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated with Live-Attenuated Tetravalent Dengue Virus Vaccines. J Infect Dis. 2012;207(5):700&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">23225894</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201(3):370&#x2013;377. doi: 10.1086/649916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/649916</ArticleId><ArticleId IdType="pubmed">20059357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003;69(6 Suppl):24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 2001;19(23&#x2013;24):3179&#x2013;3188.</Citation><ArticleIdList><ArticleId IdType="pubmed">11312014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoke CH Jr, Malinoski FJ, Eckels KH, Scott RM, Dubois DR, Summers PL, Simms T, Burrous J, Hasty SE, Bancroft WH. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg. 1990;43(2):219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">2389825</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM, Bhamarapravati N. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. 1996;14(4):329&#x2013;336. doi: 10.1016/0264-410X(95)00167-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(95)00167-Y</ArticleId><ArticleId IdType="pubmed">8744561</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL, Hoke CH. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis. 1994;170(6):1448&#x2013;1455. doi: 10.1093/infdis/170.6.1448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/170.6.1448</ArticleId><ArticleId IdType="pubmed">7995984</ArticleId></ArticleIdList></Reference><Reference><Citation>Innis BL, Eckels KH, Kraiselburd E, Dubois DR, Meadors GF, Gubler DJ, Burke DS, Bancroft WH. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis. 1988;158(4):876&#x2013;880. doi: 10.1093/infdis/158.4.876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/158.4.876</ArticleId><ArticleId IdType="pubmed">3171230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancroft WH, Top FH Jr, Eckels KH, Anderson JH Jr, McCown JM, Russell PK. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun. 1981;31(2):698&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC351366</ArticleId><ArticleId IdType="pubmed">7216469</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott RM, Eckels KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, Russell PK. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis. 1983;148(6):1055&#x2013;1060. doi: 10.1093/infdis/148.6.1055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/148.6.1055</ArticleId><ArticleId IdType="pubmed">6655288</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancroft WH, Scott RM, Eckels KH, Hoke CH Jr, Simms TE, Jesrani KD, Summers PL, Dubois DR, Tsoulos D, Russell PK. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis. 1984;149(6):1005&#x2013;1010. doi: 10.1093/infdis/149.6.1005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/149.6.1005</ArticleId><ArticleId IdType="pubmed">6376649</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckels KH, Scott RM, Bancroft WH, Brown J, Dubois DR, Summers PL, Russell PK, Halstead SB. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg. 1984;33(4):684&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">6476216</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg. 1987;36(2):435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">3826504</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin. 2006;2(4):167&#x2013;173. doi: 10.4161/hv.2.4.2944.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.2.4.2944</ArticleId><ArticleId IdType="pubmed">17012875</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K, Murphy BR, Whitehead SS. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin. 2006;2(6):255&#x2013;260. doi: 10.4161/hv.2.6.3494.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.2.6.3494</ArticleId><ArticleId IdType="pubmed">17106267</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, Murphy BR, Karron RA. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005;191(5):710&#x2013;718. doi: 10.1086/427780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/427780</ArticleId><ArticleId IdType="pubmed">15688284</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg. 2008;79(5):678&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2590927</ArticleId><ArticleId IdType="pubmed">18981503</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3&#x2032;-untranslated region. Am J Trop Med Hyg. 2001;65(5):405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">11716091</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine. 2000;18(Suppl 2):44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821973</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Dengue vaccine development: report of the twelfth peer review meeting, 29-31 August 1994. 1995 ed. New Delhi: WHO Regional Office for South-East Asia; 1994.</Citation></Reference><Reference><Citation>Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog. 2011;7(12):e1002344. doi: 10.1371/journal.ppat.1002344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002344</ArticleId><ArticleId IdType="pmc">PMC3248557</ArticleId><ArticleId IdType="pubmed">22241978</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan LP, Zhang W, Zhang L, Wu XP, Zhu XL, Yan BY, Li JY, Xu AQ, Liu Y, Li H. CD3Z genetic polymorphism in immune response to hepatitis B vaccination in two independent Chinese populations. PLoS One. 2012;7(4):e35303. doi: 10.1371/journal.pone.0035303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035303</ArticleId><ArticleId IdType="pmc">PMC3329423</ArticleId><ArticleId IdType="pubmed">22536368</ArticleId></ArticleIdList></Reference><Reference><Citation>Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, Hibberd ML, Seielstad M. New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun. 2010;11(3):232&#x2013;238. doi: 10.1038/gene.2010.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2010.1</ArticleId><ArticleId IdType="pubmed">20237496</ArticleId></ArticleIdList></Reference><Reference><Citation>Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology. 2005;41(6):1383&#x2013;1390. doi: 10.1002/hep.20716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20716</ArticleId><ArticleId IdType="pubmed">15915462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, Vollmar J, Schneider PM, Fimmers R. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet. 2002;360(9338):991&#x2013;995. doi: 10.1016/S0140-6736(02)11083-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)11083-X</ArticleId><ArticleId IdType="pubmed">12383669</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens. 1997;50(1):8&#x2013;14. doi: 10.1111/j.1399-0039.1997.tb02827.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.1997.tb02827.x</ArticleId><ArticleId IdType="pubmed">9243749</ArticleId></ArticleIdList></Reference><Reference><Citation>Png E, Thalamuthu A, Ong RT, Snippe H, Boland GJ, Seielstad M. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet. 2011;20(19):3893&#x2013;3898. doi: 10.1093/hmg/ddr302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr302</ArticleId><ArticleId IdType="pubmed">21764829</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA. 1988;260(12):1734&#x2013;1738. doi: 10.1001/jama.1988.03410120080031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1988.03410120080031</ArticleId><ArticleId IdType="pubmed">2970557</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004;39(4):978&#x2013;988. doi: 10.1002/hep.20142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20142</ArticleId><ArticleId IdType="pubmed">15057902</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Liang Z, Lu F, Fang X, Liu S, Zeng Y, Zhu F, Chen X, Shen T, Li J, Zhuang H. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine. 2011;29(4):706&#x2013;711. doi: 10.1016/j.vaccine.2010.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.11.023</ArticleId><ArticleId IdType="pubmed">21111021</ArticleId></ArticleIdList></Reference><Reference><Citation>Desombere I, Cao T, Gijbels Y, Leroux-Roels G. Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation. Clin Exp Immunol. 2005;140(1):126&#x2013;137. doi: 10.1111/j.1365-2249.2004.02749.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2004.02749.x</ArticleId><ArticleId IdType="pmc">PMC1809328</ArticleId><ArticleId IdType="pubmed">15762884</ArticleId></ArticleIdList></Reference><Reference><Citation>Erwin-Cohen R, Porter A, Pittman P, Rossi C, Dasilva L. Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83): Comparison of naive, vaccine responder and nonresponder to TC-83 challenge in human peripheral blood mononuclear cells. Hum Vacc Immunother. 2012;8(8):1053&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551876</ArticleId><ArticleId IdType="pubmed">22617845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler S, Thiel A. Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. Blood. 2009;113(4):769&#x2013;774. doi: 10.1182/blood-2008-02-139154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-02-139154</ArticleId><ArticleId IdType="pubmed">18583570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ, Kuno G, editor. Dengue And Dengue Hemorrhagic Fever, ed First. Wallingford, UK: CABI; 1997.</Citation></Reference><Reference><Citation>Rico-Hesse R. Dengue virus markers of virulence and pathogenicity. Future Virol. 2009;4(6):581. doi: 10.2217/fvl.09.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl.09.51</ArticleId><ArticleId IdType="pmc">PMC2821058</ArticleId><ArticleId IdType="pubmed">20161679</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Dengue. Lancet. 2007;370(9599):1644&#x2013;1652. doi: 10.1016/S0140-6736(07)61687-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61687-0</ArticleId><ArticleId IdType="pubmed">17993365</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8(12 Suppl):S7&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>